Marine Biotechnology, Fish Nutrition and Health Division, Central Marine Fisheries Research Institute, Ernakulam North, P.B. No. 1603, Cochin, 682018, India.
Faculty of Marine Sciences, Lakeside Campus, Cochin University of Science and Technology, Cochin, Kerala, India.
Arch Microbiol. 2022 Sep 27;204(10):648. doi: 10.1007/s00203-022-03246-5.
The inevitability to develop novel antimicrobial agents has considerably increased because of mounting alarms concerning multidrug-resistant microbial strains. The present study evaluated an antibacterial and wound healing topical formulation prepared with the ethyl acetate extract of marine symbiotic Bacillus amyloliquefaciens MTCC 12716 as the basic ingredient and the grafted macroalgal polysaccharide as the gel base with an appropriate proportion of natural stabilizing agents. The formulation exhibited potent antibacterial activities against clinical isolates of Staphylococcus aureus (18 mm inhibition zone) and Pseudomonas aeruginosa (19 mm) causing infection when compared with commercially available antimicrobial cream clindamycin. The in-vitro results indicated that the organic extract of B. amyloliquefaciens MTCC 12716 at its MIC and the formulation sealed the wound by 78 and 94%, respectively, at 48 h in the scratch-induced L929 cells, compared to 84% exhibited by clindamycin. The topical formulation of marine symbiotic Bacillus induced greater than 80% viability of the normal fibroblasts compared to 78% exhibited by clindamycin, when administered at a dose of 25 μg mL. The studied antibacterial formulation could accelerate the wound healing by prompting the migration of fibroblasts towards the artificially created wound resulting in rapid wound closure, and at an even higher concentration of formulation, it displayed no cytotoxicity on L929 cells. The stability studies showed that the formulation maintained its physicochemical characteristics and minimal growth (<10 cfu g) of bacteria on the plates throughout the time period of 18 months at 30 °C and 65% relative humidity. This study has established the antibacterial and wound healing potential of a topical formulation of marine symbiotic B. amyloliquefaciens.
由于对多药耐药微生物菌株的担忧不断增加，开发新型抗菌药物已成为必然。本研究评估了一种抗菌和伤口愈合的局部制剂，该制剂以海洋共生芽孢杆菌 MTCC 12716 的乙酸乙酯提取物为基本成分，接枝大型藻类多糖为凝胶基质，并适当添加天然稳定剂。与市售抗菌乳膏克林霉素相比，该制剂对金黄色葡萄球菌（18 毫米抑制区）和铜绿假单胞菌（19 毫米）引起的临床分离株表现出较强的抗菌活性。体外结果表明，海洋共生芽孢杆菌 MTCC 12716 的有机提取物在其 MIC 下，以及在 48 小时内，制剂分别以 78%和 94%的比例封闭划痕诱导的 L929 细胞中的伤口，而克林霉素则为 84%。与克林霉素相比，海洋共生芽孢杆菌的局部制剂在 25 μg mL 的剂量下可使正常成纤维细胞的存活率提高到 80%以上，而克林霉素则为 78%。研究中的抗菌制剂能够通过促使成纤维细胞向人工创建的伤口迁移来加速伤口愈合，从而实现快速伤口闭合，并且在制剂的更高浓度下，它对 L929 细胞没有细胞毒性。稳定性研究表明，该制剂在 30°C 和 65%相对湿度下的 18 个月内保持其物理化学特性和最小的细菌生长（<10 cfu g）。本研究确立了海洋共生芽孢杆菌局部制剂的抗菌和伤口愈合潜力。
